The American Journal of Cardiology
 

Abraham - Figure 10

CHAMPION Clinical Trial: Substantial reduction in 30-day readmissions in Medicare-eligible patients

Another frequent question that has arisen from the CHAMPION Trial data concerns whether there was an effect on 30-day hospital readmissions?  There is evidence that PAP-management reduces HF readmissions at 6 months and over longer follow-up, but there is now a strong focus on 30-day readmission rates.  To perform this further retrospective analysis we looked at Medicare-eligible CHAMPION patients who were admitted to hospital during the follow-up of the study – ie, those ≥65 years – and compared them to the Medicare database for 30-day readmissions and HF hospitalizations, looking at patients with PAP-managed care versus standard of care.  Looking at 30-day outcomes following these hospitalizations, the results showed statistically significant and clinically meaningful reductions in all-cause readmissions and HF hospitalizations in the PAP-guided treatment group compared with control patients.  For example, as seen in Figure 10 the reduction in 30-day all-cause readmissions was 58%, and in HF 30-day readmissions was 78%, for PAP-guided management vs standard care.[11]

Abraham WT. Am J Cardiol. 2015; 00.

References

[11]

Adamson PB, Abraham WT, Bauman J, Yadav J. Impact of wireless pulmonary artery pressure monitoring on heart failure hospitalizations and all-cause 30-day readmissions in Medicare-eligible patients with NYHA Class III heart failure: Results from the CHAMPION trial. Circulation. 2014;130:A16744.